INDIA CAPPED TRADE MARGINS ON 137 CANCER DRUGS, WITH LOWER PRICES DUE NOVEMBER 9.
The rule targets excessive distribution markups while requiring manufacturers to maintain supply.
India's National Pharmaceutical Pricing Authority applied a 30% trade-margin cap to 137 non-scheduled anti-cancer drugs, including immunotherapies and medicines used across more than 20 cancer types. Manufacturers must submit revised prices, which become effective November 9, 2026.
WHAT HAPPENED
The rule limits the gap between the first point of sale and maximum retail price while preserving manufacturer revenue. Government analysis found very large existing markups on some medicines. Manufacturers must maintain current production levels, disseminate revised prices and seek permission before reducing output or discontinuing covered formulations.
WHY THIS IS HOPESLOP
A cancer medicine can exist and still be inaccessible because of price. This policy attacks a specific, measurable part of that barrier—distribution and retail markups—across a large list of essential treatments. The important next test is whether the promised reductions appear in pharmacies and hospitals without supply disruptions.
ORIGINAL SOURCEPress Information Bureau of India / NPPARead the original report
A DAILY ALLEGATION OF PROGRESS.
One good thing from the internet, every day. Nothing else.